CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...